PDF herunterladen
CC BY-NC-ND 4.0 · World J Nucl Med 2022; 21(04): 296-301
DOI: 10.1055/s-0042-1750396
Original Article

Preradioactive Iodine Thyroglobulin Levels as Predictors of Metastasis in Well-Differentiated Thyroid Carcinoma Patients

Budi Darmawan
1   Department of Nuclear Medicine and Molecular Imaging, Dr. Hasan Sadikin General Hospital, Faculty of Medicine, Universitas Padjadjaran, Bandung, Bandung, Indonesia
,
Meutia Sari
2   Department of Nuclear Medicine, Adam Malik General Hospital, Medan, Indonesia
,
Stefani Susilo
1   Department of Nuclear Medicine and Molecular Imaging, Dr. Hasan Sadikin General Hospital, Faculty of Medicine, Universitas Padjadjaran, Bandung, Bandung, Indonesia
,
Achmad Hussein S. Kartamihardja
1   Department of Nuclear Medicine and Molecular Imaging, Dr. Hasan Sadikin General Hospital, Faculty of Medicine, Universitas Padjadjaran, Bandung, Bandung, Indonesia
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Objective The aim of this study was to determine the cut-off value of thyroglobulin (Tg) levels as a predictor of metastases in post total thyroidectomy patients with well-differentiated thyroid carcinoma (DTC).

Materials and Methods A retrospective case-control study with an observational diagnostic approach was done. Subjects were 102 DTC patients divided into a case group with metastases and a control group without metastases. Tg and antithyroglobulin antibody (ATA) levels on thyroid-stimulating hormone (TSH)-stimulated preradioactive iodine were compared with each other. Diagnosis of metastases was based on postradioactive iodine whole-body scan. The cut-off value for Tg preradioactive iodine and the area under the curve (AUC) were obtained from the receiver operating characteristic curve.

Result The characteristics and histopathological type of DTC among these two groups were not significantly different (p = 0.47). The Tg levels in the case and control groups were 106 (2.2–6,000) ng/mL and 2.7 (0.3–10.10) ng/mL, respectively (p = 0.0001). TSH level in the case group was 50 (30–107) µIU/mL and in the control was 50 (20–100) µIU/mL (p = 0.224). ATA levels in the case and control groups were 0–3,000 and 0–629 ng/mL, respectively (p = 0.01). The AUC was 0.976 with a 95% confidence interval of 0.924 to 0.996 and a standard error of 0.016. The cut-off value of preradioactive iodine Tg was 10.1 ng/mL or higher with sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of 96.1, 100, 98.0, 100, and 96.2%, respectively.

Conclusion Preradioactive iodine Tg level 10.1 ng/mL or higher can be used as a predictor of metastasis in patients with DTC.

Keywords

well-differentiated thyroid carcinoma - metastasis - thyroglobulin


Publikationsverlauf

Artikel online veröffentlicht:
05. September 2022

© 2022. World Association of Radiopharmaceutical and Molecular Therapy (WARMTH). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Gharib H, Papini E, Paschke R. et al; AACE/AME/ETA Task Force on Thyroid Nodules. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: executive summary of recommendations. J Endocrinol Invest 2010; 33 (5, Suppl): 51-56
    CrossrefPubMedGoogle Scholar
  • 2 Cooper DS, Doherty GM, Haugen BR. et al; American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19 (11) 1167-1214
    CrossrefPubMedGoogle Scholar
  • 3 Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006; 154 (06) 787-803
    CrossrefPubMedGoogle Scholar
  • 4 Haugen BR, Alexander EK, Bible KC. et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016; 26 (01) 1-133
    Google Scholar
  • 5 Verburg FA, de Keizer B, Lips CJ, Zelissen PM, de Klerk JM. Prognostic significance of successful ablation with radioiodine of differentiated thyroid cancer patients. Eur J Endocrinol 2005; 152 (01) 33-37
    CrossrefPubMedGoogle Scholar
  • 6 Pacini F, Ladenson PW, Schlumberger M. et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 2006; 91 (03) 926-932
    CrossrefPubMedGoogle Scholar
  • 7 Hagag P, Strauss S, Weiss M. Role of ultrasound-guided fine-needle aspiration biopsy in evaluation of nonpalpable thyroid nodules. Thyroid 1998; 8 (11) 989-995
    CrossrefPubMedGoogle Scholar
  • 8 Wexler JA. Approach to the thyroid cancer patient with bone metastases. J Clin Endocrinol Metab 2011; 96 (08) 2296-2307
    CrossrefPubMedGoogle Scholar
  • 9 Robenshtok E, Fish S, Bach A, Domínguez JM, Shaha A, Tuttle RM. Suspicious cervical lymph nodes detected after thyroidectomy for papillary thyroid cancer usually remain stable over years in properly selected patients. J Clin Endocrinol Metab 2012; 97 (08) 2706-2713
    CrossrefPubMedGoogle Scholar
  • 10 Schlumberger M, Pacini F. eds. Papillary and follicular thyroid carcinoma. Follow-up: lessons from the past. In: Thyroid Tumors. 2nd ed. Paris: Nucleon; 2006: 147-164
    Google Scholar
  • 11 Rosário PW, Ward LS, Carvalho GA. et al; Sociedade Brasileira de Endocrinologia e Metabologia. Thyroid nodules and differentiated thyroid cancer: update on the Brazilian consensus. Arq Bras Endocrinol Metabol 2013; 57 (04) 240-264
    CrossrefPubMedGoogle Scholar
  • 12 Muratet JP, Giraud P, Daver A, Minier JF, Gamelin E, Larra F. Predicting the efficacy of first iodine-131 treatment in differentiated thyroid carcinoma. J Nucl Med 1997; 38 (09) 1362-1368
    PubMedGoogle Scholar
  • 13 Park HJ, Jeong GC, Kwon SY. et al. Stimulated serum thyroglobulin level at the time of first dose of radioactive iodine therapy is the most predictive factor for therapeutic failure in patients with papillary thyroid carcinoma. Nucl Med Mol Imaging 2014; 48 (04) 255-261
    CrossrefPubMedGoogle Scholar
  • 14 Shah J, Patel SG, Singh B. eds. Jatin Shah's Head and Neck Surgery Oncology. 4th ed. Philadelphia, PA: Elsevier; 2012: 471-525
    Google Scholar
  • 15 McDougall IR. ed. Thyroid Cancer in Clinical Practice. 1st ed. London: Spinger; 2007: 53-91
    CrossrefGoogle Scholar
  • 16 American Cancer Society. Alabama cancer facts & figures [Internet]. Atlanta, GA: American Cancer Society; 2015. Accessed May 20, 2016 at: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2021.html
    Google Scholar
  • 17 Mazzaferri EL, Robbins RJ, Spencer CA. et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003; 88 (04) 1433-1441
    CrossrefPubMedGoogle Scholar
  • 18 American Cancer Society. Key statistics about thyroid cancer [Internet]. Atlanta, GA: American Cancer Society; 2015. Accessed January 12, 2015 at: https://www.cancer.org/cancer/thyroid-cancer/about/key-statistics.html
  • 19 Cooper DS, Doherty GM, Haugen BR. et al; American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19 (11) 1167-1214
    CrossrefPubMedGoogle Scholar
  • 20 Rosário PW, Reis JS, Barroso AL, Rezende LL, Padrão EL, Fagundes TA. Efficacy of low and high 131I doses for thyroid remnant ablation in patients with differentiated thyroid carcinoma based on post-operative cervical uptake. Nucl Med Commun 2004; 25 (11) 1077-1081
    CrossrefPubMedGoogle Scholar
  • 21 Tuttle RM, Sabra MM. Selective use of RAI for ablation and adjuvant therapy after total thyroidectomy for differentiated thyroid cancer: a practical approach to clinical decision making. Oral Oncol 2013; 49 (07) 676-683
    CrossrefPubMedGoogle Scholar
  • 22 Elrasad S, Abdelhafez Y, Abdelkareem M, Amin R, Elrefaei S. The value of postoperative baseline serum thyroglobulin in prediction of the outcome of radioactive I-131 thyroid ablation in differentiated thyroid carcinoma. Egyptian J Nucl Med 2014; 10 (02) 73-84
    CrossrefGoogle Scholar
  • 23 Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinchera A. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab 2002; 87 (04) 1499-1501
    CrossrefPubMedGoogle Scholar
  • 24 Lee HJ, Rha SY, Jo YS. et al. Predictive value of the preablation serum thyroglobulin level after thyroidectomy is combined with postablation 131I whole body scintigraphy for successful ablation in patients with differentiated thyroid carcinoma. Am J Clin Oncol 2007; 30 (01) 63-68
    CrossrefPubMedGoogle Scholar
  • 25 Polachek A, Hirsch D, Tzvetov G. et al. Prognostic value of post-thyroidectomy thyroglobulin levels in patients with differentiated thyroid cancer. J Endocrinol Invest 2011; 34 (11) 855-860
    PubMedGoogle Scholar
  • 26 Cabezón C, Löwenstein A, Orlandi A, Sartorio G, Sobrado P. Miembros del Departamento de Tiroides de la Sociedad Argentina de Endocrinología y Metabolismo (SAEM). Usefulness of preablation serum thyroglobulin as a predictor of the evolution of patients with differentiated thyroid carcinoma. Rev Argent Endocrinol Metab 2011; 48 (04) 25-33
    Google Scholar
  • 27 Park EK, Chung JK, Lim IH. et al. Recurrent/metastatic thyroid carcinomas false negative for serum thyroglobulin but positive by posttherapy I-131 whole body scans. Eur J Nucl Med Mol Imaging 2009; 36 (02) 172-179
    CrossrefPubMedGoogle Scholar
  • 28 Van Nostrand D, Aiken M, Atkins F. et al. The utility of radioiodine scans prior to iodine 131 ablation in patients with well-differentiated thyroid cancer. Thyroid 2009; 19 (08) 849-855
    CrossrefPubMedGoogle Scholar
  • 29 Schlumberger MJ, Pacini F. The low utility of pretherapy scans in thyroid cancer patients. Thyroid 2009; 19 (08) 815-816
    CrossrefPubMedGoogle Scholar
  • 30 McDougall IR. The case for obtaining a diagnostic whole-body scan prior to iodine 131 treatment of differentiated thyroid cancer. Thyroid 2009; 19 (08) 811-813
    CrossrefPubMedGoogle Scholar
  • 31 Cailleux AF, Baudin E, Travagli JP, Ricard M, Schlumberger M. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer?. J Clin Endocrinol Metab 2000; 85 (01) 175-178
    CrossrefPubMedGoogle Scholar
  • 32 Baudin E, Do Cao C, Cailleux AF, Leboulleux S, Travagli JP, Schlumberger M. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. J Clin Endocrinol Metab 2003; 88 (03) 1107-1111
    CrossrefPubMedGoogle Scholar
  • 33 Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 2008; 93 (02) 504-515
    CrossrefPubMedGoogle Scholar
  • 34 Rubino C, de Vathaire F, Dottorini ME. et al. Second primary malignancies in thyroid cancer patients. Br J Cancer 2003; 89 (09) 1638-1644
    CrossrefPubMedGoogle Scholar
  • 35 Ronckers CM, McCarron P, Ron E. Thyroid cancer and multiple primary tumors in the SEER cancer registries. Int J Cancer 2005; 117 (02) 281-288
    CrossrefPubMedGoogle Scholar
  • 36 Hyer S, Kong A, Pratt B, Harmer C. Salivary gland toxicity after radioiodine therapy for thyroid cancer. Clin Oncol (R Coll Radiol) 2007; 19 (01) 83-86
    CrossrefPubMedGoogle Scholar
  • 37 Alexander C, Bader JB, Schaefer A, Finke C, Kirsch CM. Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma. J Nucl Med 1998; 39 (09) 1551-1554
    PubMedGoogle Scholar
  • 38 Müller-Gärtner HW, Schneider C. Clinical evaluation of tumor characteristics predisposing serum thyroglobulin to be undetectable in patients with differentiated thyroid cancer. Cancer 1988; 61 (05) 976-981
    CrossrefPubMedGoogle Scholar
  • 39 Spencer C, Petrovic I, Fatemi S. Current thyroglobulin autoantibody (TgAb) assays often fail to detect interfering TgAb that can result in the reporting of falsely low/undetectable serum Tg IMA values for patients with differentiated thyroid cancer. J Clin Endocrinol Metab 2011; 96 (05) 1283-1291
    CrossrefPubMedGoogle Scholar
  • 40 Lim D-J, O JH, Kim M-H. et al. Clinical significance of observation without repeated radioiodine therapy in differentiated thyroid carcinoma patients with positive surveillance whole-body scans and negative thyroglobulin. Korean J Intern Med 2010; 25 (04) 408-414
    CrossrefPubMedGoogle Scholar
  • 41 Spencer CA, Bergoglio LM, Kazarosyan M, Fatemi S, LoPresti JS. Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas. J Clin Endocrinol Metab 2005; 90 (10) 5566-5575
    CrossrefPubMedGoogle Scholar
  • 42 Rubio IG, Silva MN, Knobel M. et al. Peripheral blood levels of thyroglobulin mRNA and serum thyroglobulin concentrations after radioiodine ablation of multinodular goiter with or without pre-treatment with recombinant human thyrotropin. J Endocrinol Invest 2007; 30 (07) 535-540
    CrossrefPubMedGoogle Scholar
  • 43 Benvenga S, Bartolone L, Squadrito S, Trimarchi F. Thyroid hormone autoantibodies elicited by diagnostic fine needle biopsy. J Clin Endocrinol Metab 1997; 82 (12) 4217-4223
    PubMedGoogle Scholar
  • 44 Kim WG, Yoon JH, Kim WB. et al. Change of serum antithyroglobulin antibody levels is useful for prediction of clinical recurrence in thyroglobulin-negative patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 2008; 93 (12) 4683-4689
    CrossrefPubMedGoogle Scholar
  • 45 Brendel AJ, Lambert B, Guyot M. et al. Low levels of serum thyroglobulin after withdrawal of thyroid suppression therapy in the follow up of differentiated thyroid carcinoma. Eur J Nucl Med 1990; 16 (01) 35-38
    CrossrefPubMedGoogle Scholar
  • 46 Mertens IJ, De Klerk JM, Zelissen PM. et al. Undetectable serum thyroglobulin in a patient with metastatic follicular thyroid cancer. Clin Nucl Med 1999; 24 (05) 346-349
    CrossrefPubMedGoogle Scholar
  • 47 Torréns JI, Burch HB. Serum thyroglobulin measurement. Utility in clinical practice. Endocrinol Metab Clin North Am 2001; 30 (02) 429-467
    CrossrefPubMedGoogle Scholar